Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

The only FDA-approved, fully human,* anti-EGFR, monoclonal antibody1

*Correlation with safety and efficacy is unknown.

Q2W dosing

The recommended dose of Vectibix® is 6 mg/kg every 14 days1

NO

standardized premedication was required in clinical trials1

The utility of premedication in preventing infusion toxicity is unknown1

NO

loading dose1

60-minute IV infusion1

  • Doses of ≤ 1,000 mg should be administered over 60 minutes
  • If the first infusion is tolerated, the subsequent infusions may be administered over 30 to 60 minutes1
  • Doses of > 1,000 mg should be administered over 90 minutes1

EGFR = epidermal growth factor receptor; Q2W = every two weeks.

Site Map
×